Skip to content
Home/Companies/Biotech/Oncoethix

Oncoethix

Biotech·Belgium·Exited 2014·Held 1yr
Entry
2013
Hold
1yr
Exit
2014

Who owns Oncoethix?

Oncoethix is a Belgian Biotech company, now owned by Merck & Co., which acquired it in 2014 from Andera Partners.

Hand-verified · updated 2026-04-21

Open JSON · CC-BY
Andera Partners
Investor
Andera Partners
BioDiscovery 4 · 2013 · VC

Key facts

HQBelgium
SectorBiotech
Exit Type
Trade Sale
Buyer
Merck & Co.
Exit Year
2014

More from BioDiscovery 4

Other portfolio companies in the same fund.

Inotrem
Active
BiotechFrance
MedDay Pharmaceuticals
Exited 2021
BiotechFrance· 2016
Verona Pharma
Verona Pharma
Exited 2017
BiotechUK· 2016
Autonomic Technologies
Exited 2020
MedTechUS· 2015
to Unity HA
Gamamabs
Active
BiotechFrance· 2015
ReViral
Exited 2022
BiotechUK· 2015
to Pfizer

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Oncoethix?

Oncoethix is now owned by Merck & Co., which acquired it in 2014 from Andera Partners.

When did Merck & Co. acquire Oncoethix?

Merck & Co. acquired Oncoethix in 2014, buying from Andera Partners.

Who did Oncoethix sell to?

Andera Partners sold Oncoethix to Merck & Co. in 2014 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue